Medistim ASA is a publicly listed company with head office in Oslo, Norway. The company develops, manufactures and distributes medical devices that measure blood flow and visualize atherosclerosis, contributing to improved quality and outcomes of cardiac and vascular surgery. Medistim is an innovator and market leader within intraoperative transit time blood measurement (TTFM) and ultrasound imaging, with the products VeriQ™, VeriQ C™ and the newest generation, MiraQ™ on the global market.
These devices provide surgeons with clinically relevant information that enables them to make better-informed decisions during surgery, ultimately reducing the patients’ risk of stroke and death. The TTFM-technology was included in the ESC / EACTS guidelines for myocardial revascularization in 2010 and given continued recommendation in 2018. In 2011, the British National Institute for Health and Clinical Excellence (NICE) recommended that the VeriQ™ device should be implemented and used routinely within the British National Health System (NHS). In 2016, Medistim’s technology gained reimbursement in Japan for routine use of blood flow measurement and intraoperative ultrasound imaging during coronary artery bypass grafting (CABG).
Medistim has wholly-owned subsidiaries with marketing and sales teams in the USA, Germany, the UK, Spain, Denmark and Norway, in addition to a global distributor network in more than 50 countries around the globe.